Your browser doesn't support javascript.
loading
Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
Camblin, Adam J; Tan, Gege; Curley, Michael D; Yannatos, Isabel; Iadevaia, Sergio; Rimkunas, Victoria; Mino-Kenudson, Mari; Bloom, Troy; Schoeberl, Birgit; Drummond, Daryl C; Lugovskoy, Alexey A; Louis, Chrystal U; Askoxylakis, Vasileios.
Afiliación
  • Camblin AJ; Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA. adam.camblin@gmail.com.
  • Tan G; Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Curley MD; Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Yannatos I; Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Iadevaia S; Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Rimkunas V; Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Mino-Kenudson M; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Bloom T; Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Schoeberl B; Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Drummond DC; Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Lugovskoy AA; Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Louis CU; Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Askoxylakis V; Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA. v.askoxylakis@gmail.com.
Sci Rep ; 9(1): 16832, 2019 11 14.
Article en En | MEDLINE | ID: mdl-31728045
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Receptor IGF Tipo 1 / Resistencia a Antineoplásicos / Receptor ErbB-3 / Anticuerpos Monoclonales Humanizados / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Sci Rep Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Receptor IGF Tipo 1 / Resistencia a Antineoplásicos / Receptor ErbB-3 / Anticuerpos Monoclonales Humanizados / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Sci Rep Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos